Status:
COMPLETED
Safety, Tolerability and Pharmacokinetic Study of MT-3995 in Subjects With Diabetic Nephropathy
Lead Sponsor:
Tanabe Pharma Corporation
Conditions:
Diabetic Nephropathy
Eligibility:
All Genders
20-75 years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to evaluate safety, tolerability and pharmacokinetics of MT-3995 in Subjects with Diabetic Nephropathy
Eligibility Criteria
Inclusion
- Subjects with Type 2 diabetes mellitus and diabetic nephropathy, who have been treated with a stable dose of angiotensin converting enzyme-inhibitor (ACE-I) or angiotensin II receptor blocker (ARB)
- Glycosylated haemoglobin (HbA1c) ≤10.5%
- Subject with albuminuria
Exclusion
- History of Type 1 diabetes, pancreas or β-cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy.
- Serum potassium level \<3.5 or \>5.0 mmol/L
- Subjects who had acute kidney injury within 3 months prior to baseline or have undergone hemodialysis at any time prior to randomisation
- Subjects with clinically significant hypotension
Key Trial Info
Start Date :
July 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2015
Estimated Enrollment :
51 Patients enrolled
Trial Details
Trial ID
NCT01889277
Start Date
July 1 2013
End Date
January 1 2015
Last Update
January 27 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Koukan Hospital
Kawasaki, Kanagawa Pref., Japan